Dewi P. I. Moonen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dewi P. I. Moonen has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Andreas R. Gschwind
Department of Genetics, Stanford University School of Medicine, Stanford, USA
2 shared publications - Daniel Schraivogel
Genome Biology Unit, European Molecular Biology Laboratory (EMBL), Heidelberg, Germany
2 shared publications - Lars M. Steinmetz
Genome Biology Unit, European Molecular Biology Laboratory (EMBL), Heidelberg, Germany
2 shared publications - Annique Claringbould
European Molecular Biology Laboratory, Genome Biology Unit, Heidelberg, Germany
1 shared publication - Aruna Ayer
Waters Biosciences; Milpitas, CA, USA
1 shared publication - Benedikt Rauscher
European Molecular Biology Laboratory (EMBL), Genome Biology Unit; Heidelberg, Germany
1 shared publication
Latest Publications
- 26 May 2026
- Published by Springer Nature in Nature Protocols
- Vol. 21 (11) , 5106-5127
Targeted single-cell RNA and perturbation sequencing with TAP-seq
Pooled genome editing combined with single-cell RNA sequencing-commonly known as Perturb-seq-has transformed the ability to interrogate genome function. However, whole-transcriptome single-cell RNA sequencing requires high sequencing depth to achieve the sensitivity needed for functional genomics screens, limiting its widespread use owing to prohibitive cost. Here we describe a detailed and updated protocol for targeted Perturb-seq (TAP-seq), a method that addresses the sensitivity and cost limitations of Perturb-seq. Instead of capturing the whole transcriptome, TAP-seq focuses on quantifying hundreds of transcripts of interest. The TAP-seq workflow involves first selecting genes for targeted readout, designing primers, conducting an initial pilot experiment and finally performing the TAP-seq screen and analyzing the data. We provide comprehensive guidance on designing targeted readout strategies for TAP-seq and describe all steps of the protocol, starting with library preparation. The outcome of TAP-seq is single-cell measurements of selected gene and guide RNA expression levels, guide RNA assignments to individual cells and differential expression results revealing perturbation effects on target genes. We further include instructions for adapting TAP-seq to all currently available single-cell RNA-sequencing platforms. Prior experience in single-cell technologies is beneficial and the protocol described can be completed in 2 days (excluding data analysis). In summary, this protocol describes how to perform sensitive, scalable and cost-effective single-cell perturbation screens.
- 26 May 2026
- Published by Springer Nature in Nature Protocols
- Vol. 21 (11) , 5106-5127
Targeted single-cell RNA and perturbation sequencing with TAP-seq
Pooled genome editing combined with single-cell RNA sequencing-commonly known as Perturb-seq-has transformed the ability to interrogate genome function. However, whole-transcriptome single-cell RNA sequencing requires high sequencing depth to achieve the sensitivity needed for functional genomics screens, limiting its widespread use owing to prohibitive cost. Here we describe a detailed and updated protocol for targeted Perturb-seq (TAP-seq), a method that addresses the sensitivity and cost limitations of Perturb-seq. Instead of capturing the whole transcriptome, TAP-seq focuses on quantifying hundreds of transcripts of interest. The TAP-seq workflow involves first selecting genes for targeted readout, designing primers, conducting an initial pilot experiment and finally performing the TAP-seq screen and analyzing the data. We provide comprehensive guidance on designing targeted readout strategies for TAP-seq and describe all steps of the protocol, starting with library preparation. The outcome of TAP-seq is single-cell measurements of selected gene and guide RNA expression levels, guide RNA assignments to individual cells and differential expression results revealing perturbation effects on target genes. We further include instructions for adapting TAP-seq to all currently available single-cell RNA-sequencing platforms. Prior experience in single-cell technologies is beneficial and the protocol described can be completed in 2 days (excluding data analysis). In summary, this protocol describes how to perform sensitive, scalable and cost-effective single-cell perturbation screens.
- Open Access
Genome-scale mapping of variant, enhancer and gene function in primary human CD4+ T cells
CD4+ T cells harbor a disproportionate enrichment of immune disease risk loci and represent the primary cellular context for immune disease biology, yet the genes and regulatory programs these variants affect remain largely unknown. We combined targeted Perturb-seq of 1,032 cis -regulatory elements (CREs) overlapping 4,724 variants across 14 immune diseases with genome-wide Perturb-seq of all expressed genes in primary human CD4+ T cells, spanning 4.1 million cells. We identified 626 CRE-gene pairs, and connected CRE targets to downstream regulatory cascades. At the TYK2 and DEXI /CLEC16A loci, we resolved target genes and linked noncoding variants to inflammatory and metabolic programs. Across diseases, we revealed that dispersed variants converged on shared and disease-specific programs. Our work provides a framework for tracing variant-to-CRE-to-gene-to-network in disease-relevant primary cells.
Open AccessGenome-scale mapping of variant, enhancer and gene function in primary human CD4+ T cells
CD4+ T cells harbor a disproportionate enrichment of immune disease risk loci and represent the primary cellular context for immune disease biology, yet the genes and regulatory programs these variants affect remain largely unknown. We combined targeted Perturb-seq of 1,032 cis -regulatory elements (CREs) overlapping 4,724 variants across 14 immune diseases with genome-wide Perturb-seq of all expressed genes in primary human CD4+ T cells, spanning 4.1 million cells. We identified 626 CRE-gene pairs, and connected CRE targets to downstream regulatory cascades. At the TYK2 and DEXI /CLEC16A loci, we resolved target genes and linked noncoding variants to inflammatory and metabolic programs. Across diseases, we revealed that dispersed variants converged on shared and disease-specific programs. Our work provides a framework for tracing variant-to-CRE-to-gene-to-network in disease-relevant primary cells.